Shangdong Dong-E Spins Off Donkey Meat Business
This article was originally published in PharmAsia News
Shangdong Dong-E E-Jiao Group's foray into the donkey meat business has received orders worth over 40 million yuan since its entry in 2007. Targeting sales of 600 million yuan over the next three years, the firm has invested 120 million yuan to make it China's top brand. The spinoff business arose from Dong-E's bid to secure more donkey-hide gelatin, a pharmaceutical raw material in short supply. In fact, many traditional Chinese medicine enterprises face the same problem of limited supply; experts advise that these companies should consider extending their strategy to upstream raw materials like what Dong-E is doing. (Click here for more - Chinese Language)
You may also be interested in...
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.